--- title: "23:20 ETU.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278196164.md" description: "Jiahui International Cancer Center (JICC) in China has successfully stabilized a U.S. patient with advanced non-small cell lung cancer (NSCLC) using ivonescimab, a novel immunotherapy. The patient, who had previously exhausted all standard treatments, received care from a multidisciplinary team, including U.S.-trained oncologists. Despite developing complications requiring ICU care, the patient's condition has stabilized. JICC is gaining recognition as a global hub for advanced cancer care, attracting patients from around the world." datetime: "2026-03-07T04:22:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278196164.md) - [en](https://longbridge.com/en/news/278196164.md) - [zh-HK](https://longbridge.com/zh-HK/news/278196164.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278196164.md) | [English](https://longbridge.com/en/news/278196164.md) # 23:20 ETU.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China , /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China. Continue Reading Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, stands on the patient’s right. The patient’s daughter, nursing team, medical team, and caregivers are gathered together at Jiahui International Hospital. The 70‑something patient had exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD‑1/VEGF bispecific antibody for solid tumors. After a video consultation in late November scheduled within a week of their initial inquiry, the family chose Jiahui International Cancer Center in Shanghai for its multidisciplinary expertise and U.S.‑trained Medical Oncology Chief Dr. XUAN Linli. During treatment, the patient developed immune‑related complications requiring ICU care. The cancer center rapidly coordinated oncology, neurology, critical care, and expert input from ivonescimab principal investigator Dr. Zhou Caicun. His condition has since stabilized, with ongoing care focused on disease control. As a tertiary international hospital partnered with Massachusetts General Hospital Cancer Center, Jiahui provides seamless international patient pathways, from remote consultations to travel coordination and continuous family updates. The patient's daughter said, "We are deeply grateful for the dedication, compassion, and tireless efforts of the entire Jiahui team: the doctors, nurses, kitchen and cleaning staff, the international team and front desk, and the care aides. My father would especially like to express his heartfelt thanks to Ms. Cui, who has cared for him every day since his admission. Beyond her attentive bedside care, she has offered him encouragement, comfort, and hope." China's breakthrough oncology innovations are creating new options for patients worldwide. JICC continues to draw growing inquiries and referrals from North America, Europe, Asia and the Middle East, establishing Shanghai as a global hub for advanced cancer care. The full story: https://jiahui.com/en/news/181 **Contact:** **International Patient Services** inter\[email protected\] WhatsApp: +852 4619 1904 SOURCE Jiahui International Hospital ### 相關股票 - [AKESO (09926.HK)](https://longbridge.com/zh-HK/quote/09926.HK.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) ## 相關資訊與研究 - [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-HK/news/278445287.md) - [Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%](https://longbridge.com/zh-HK/news/278491064.md) - [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-HK/news/278376120.md) - [Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables](https://longbridge.com/zh-HK/news/278349440.md) - [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/zh-HK/news/277818646.md)